• eTheRNA
  • Follow our progress in developing products that have the potential to transform the future of cancer treatment

eTheRNA to present at Sachs’ 4th Annual Immuno-Oncology BD&L and Investment Forum

Niel (Belgium), 31 May 2018 — eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that Acting CEO Marc Dechamps will present an overview of the Company, its technology and ongoing and planned clinical trials at Sachs’ 4th Annual Immuno-Oncology BD&L and Investment Forum on 1 June in Chicago, US.

Details of the presentation are as follows:

Date: Friday 1 June 2018
Time: 15:40-16:00
Location: Sinclair North, Waldorf Astoria Chicago Hotel

eTheRNA enrols first patient in high dose cohort of Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma

Niel (Belgium), 24 May 2018 — eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that it has enrolled the first patient in the high dose cohort of its Phase 1b study (E011-MEL) of ECI-006 as an adjuvant therapy in metastatic melanoma patients.

The high dose cohort (1800 µg) of the E011-MEL study aims to recruit ten patients, at centers in Belgium and Spain, who will receive five injections of ECI-006 administered intranodally over a period of 14 weeks.

eTheRNA to present at Bio€quity Europe

Niel (Belgium), 14 May 2018 — eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that Acting CEO Marc Dechamps will present at Bio€quity Europe, which takes place from 14-16 May in Ghent, Belgium.

The presentation will provide an overview of the Company as well as ongoing and planned clinical trials for the development of its directly injectable formulations of cancer immunotherapies based on its innovative mRNA TriMix platform. Details for the presentation are as follows:

Date: Tuesday 15 May 2018
Time: 16:40-17:00
Location: Level 1+, Priorzaal, Het Pand, Ghent University

Tijd 50 - De Belgen die uw leven zullen redden

Welke ondernemers, dokters en wetenschappers maken het verschil in onze gezondheidszorg?

De Tijd ging op zoek naar de vijftig ondernemers, onderzoekers, dokters en mecenassen die het verschil maken in de gezondheidszorg. Of ze nu aan het hoofd staan van een onderzoeksafdeling van 40.000 man, of in een labo toevallig de helende kwaliteiten van het bloed van kamelen ontdekten, stuk voor stuk bewijzen ze dat toewijding, vakkennis en innovatie grenzen verleggen in de ultieme strijd van ons allen: die tegen de dood.